Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Venus Leg Ulcers
Interventions: EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC); Drug · Other
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Maimi, Florida

Conditions: Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
Interventions: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM); Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Adults, Venous Leg Ulcer
Interventions: Pressure and Temperature Sensor; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Foot Ulcer, Diabetes Mellitus, Type 2
Interventions: EnhanceFitness community exercise program; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ulcer, Leg Ulcer, Varicose Ulcer, Pathologic Processes, Skin Ulcer, Skin Diseases, Vascular Diseases, Cardiovascular Diseases
Interventions: Placebo, VF001-DP LD, VF001-DP HD; Biological
Lead sponsor: Factor Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 17
States / cities: Carlsbad, California • Fresno, California • Laguna Hills, California + 10 more

Conditions: Colitis Ulcerative
Interventions: SAR443122, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Lancaster, California • Atlanta, Georgia • Evanston, Illinois + 10 more

Conditions: Diabetic Foot, Foot Ulcer; Diabetic
Interventions: Offloading, Dressing Application; Device · Procedure
Lead sponsor: Lower Extremity Institute for Research and Therapy; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 3
States / cities: Canfield, Ohio • Danville, Virginia • Troutville, Virginia

Conditions: Colitis, Ulcerative, Crohn Disease
Interventions: Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Cypress, California • Miami, Florida

Conditions: Ulcerative Colitis (UC)
Interventions: TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 36
States / cities: Chula Vista, California • Lancaster, California • Orange, California + 32 more

Conditions: Upper Gastrointestinal Bleeding
Interventions: Clinician notification, Clinician Notification with Nurse Facilitation, Clinician Notification / Patient Activation, Clinician Notification with Nurse Facilitation / Patient Activation; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetic Foot Ulcer
Interventions: Noveon laser; Device
Lead sponsor: Nomir Medical Technologies; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Ulcerative Colitis
Interventions: PF-06687234, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 14
States / cities: Dothan, Alabama • Atlanta, Georgia • Chevy Chase, Maryland + 6 more

Conditions: Peripheral Arterial Disease Below the Knee, Peripheral Arterial Disease, Rutherford 4 and 5 with Possibility to Improve Vascularization
Interventions: Multicath, Standard of Care (SOC); Device
Lead sponsor: Summa Therapeutics, LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Wilmington, Delaware • Vineland, New Jersey

Conditions: Colitis, Ulcerative
Interventions: Delayed and extended release mesalazine; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pyoderma Gangrenosum
Interventions: Dehydrated human amnion/chorion membrane; Biological
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Metairie, Louisiana • New Orleans, Louisiana

Conditions: Ulcerative Proctitis
Interventions: Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Twice daily placebo suppository administered with Sephure applicator; Combination Product
Lead sponsor: Cristcot HCA LLC; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 51
States / cities: Huntsville, Alabama • Apple Valley, California • Camarillo, California + 40 more

Conditions: Pressure Injuries, Pressure Ulcer Prevention
Interventions: A gamified mobile learning, Booklet training; Device · Other
Lead sponsor: Mehmet Akif Ersoy University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Interventions: Vancomycin (POC), Fidaxomicin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Foot Ulcer, Diabetic
Interventions: Transcutaneous O2 device; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Palatal Neoplasms, Lip Neoplasm, Gingival Neoplasms, Leukoplakia, Oral, Tongue Neoplasms, Oropharyngeal Neoplasms, Oral Ulcer
Interventions: OncAlert; Device
Lead sponsor: Vigilant Biosciences, Inc.; Industry
Eligibility: 23 Years and older
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 26
States / cities: Beverly Hills, California • La Mesa, California • Loma Linda, California + 22 more

Conditions: Venous Leg Ulcer
Interventions: Varithena; Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Palo Alto, California • Sacramento, California • Darien, Connecticut + 10 more

Conditions: Pressure Ulcers
Interventions: Nutritional Supplement/Amino acids and HMB, Juven; Dietary Supplement
Lead sponsor: Central Arkansas Veterans Healthcare System; Federal
Eligibility: 21 Years to 90 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Colitis, Ulcerative
Interventions: Placebo, Golimumab 50 mg, Golimumab 100 mg, Golimumab 200 mg; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 96
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 93 more

Conditions: Ulcerative Colitis
Interventions: Visilizumab; Drug
Lead sponsor: Facet Biotech; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 4 more

Search by objective public record fields.

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

Pressure and Temperature Sensor for Therapeutic Compression Garments

Effects of a Exercise Program on Health Outcomes in People With Diabetic Foot Ulcers

Study of VF001-DP in Patients With Chronic Venous Leg Ulcers

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial

Bioburden Reduction of Diabetic Foot Ulcer

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

Below-the-Knee Interventions for Limb Salvage: Use of Multifunctional Angioplasty Balloon Catheters

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

A Novel Therapeutic Treatment of Pyoderma Gangrenosum

Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Gamified Learning for Pressure Injury Prevention

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers

Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making

Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)

Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

Research Study in Patients With Severe Ulcerative Colitis